Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | APP | P05067 | 2/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CDK9 | P50750 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL1939053 | 0.94 | HDAC1 (0.54) | HTR7APPADORA2AADORA2BADORA1 | |
| SCHEMBL14869430 | 0.91 | HTR7 (0.64) | HTR7ADORA2AADORA1GAAACKR3 | |
| SCHEMBL21983872 | 0.90 | HTR7 (0.63) | HTR7GAAACKR3HTR2B | |
| SCHEMBL2451092 | 0.89 | APP (0.64) | HTR7APPADORA2AADORA2BADORA1 | |
| SCHEMBL14869439 | 0.85 | GAA (0.71) | APPADORA2AGAAHTR2B | |
| SCHEMBL14869438 | 0.84 | HTR7 (0.60) | HTR7APPADORA2AADORA2BADORA1 | |
| SCHEMBL29609013 | 0.84 | HTR7 (0.60) | HTR7APPADORA2AADORA2BADORA1 | |
| SCHEMBL14869457 | 0.83 | APP (0.58) | APPADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL14869410 | 0.81 | CA1 (0.56) | HTR7APPADORA2AADORA2BADORA1 | |
| SCHEMBL14869324 | 0.80 | CA1 (0.44) | HTR7APPADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2941245-B1 | DELAYED-RELEASE COMPOSITION COMPRISING BIGUANIDE | ANJI PHARMACEUTICALS INC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230285330-A9 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230285330-A9 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2023-09-14 | — | — | US | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2021-07-20 | — | — | US | disclosed |
| EP-2800561-B1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMA US LLC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2020-05-07 | — | — | US | disclosed |
| WO-2014107617-A1 | DELAYED-RELEASE COMPOSITION COMPRISING BIGUANIDE | ELCELYX THERAPEUTICS, INC. (US) | 2014-07-10 | — | — | WO | disclosed |
| WO-2014011926-A1 | COMPOSITIONS COMPRISING STATINS, BIGUANIDES AND FURTHER AGENTS FOR REDUCING CARDIOMETABOLIC RISK | ELCELYX THERAPEUTICS, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| WO-2013103919-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| US-20130177604-A1 | Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2013103384-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| US-20130177604-A1 | Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20110207926-A1 | NOVEL DIHYDROTRIAZINE DERIVATIVE | HAMARI CHEMICALS, LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2332925-A1 | NOVEL DIHYDROTRIAZINE DERIVATIVE | Hamari Chemicals, Ltd. (JP) | 2011-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | HTR7 1175/4885APP 2243/4885ADORA2A 808/4885 |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | HTR7 1175/4885APP 2243/4885ADORA2A 808/4885 |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | HTR7 1175/4885APP 2243/4885ADORA2A 808/4885 |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | HTR7 1175/4885APP 2243/4885ADORA2A 808/4885 |
| US-20130177604-A1 | Compositions and Methods of Treating Metabolic Disorders | FABP2, GPR119, PNLIP | HTR7 1495/4885APP 3836/4885ADORA2A 1870/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | HTR7 1175/4885APP 2243/4885ADORA2A 808/4885 |
| US-20230285330-A9 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | FABP2, GPR119, PNLIP | HTR7 1351/4885APP 3552/4885ADORA2A 1725/4885 |
| US-20110207926-A1 | NOVEL DIHYDROTRIAZINE DERIVATIVE | QDPR, DRD4, DRD1 | HTR7 1595/4885APP 1162/4885ADORA2A 3963/4885 |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GCG | HTR7 1064/4885APP 2074/4885ADORA2A 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.